Roger E. Susi, CEO, President, and Chairman of IRADIMED CORPORATION (IRMD +0.04%), reported the indirect sale of 7,500 shares of common stock across multiple open-market transactions on May 26, 2026 and May 27, 2026, according to a SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (indirect) | 7,500 |
| Transaction value | $691,000 |
| Post-transaction shares (direct) | 0 |
| Post-transaction shares (indirect) | 2,165,000 |
| Post-transaction value (direct ownership) | ~$0 |
Transaction value based on SEC Form 4 weighted average purchase price ($92.14); post-transaction value as reported in SEC Form 4 was $0.00 using the May 27, 2026 trade-date close price.
Key questions
- How does the transaction compare to Susi's historical sale sizes and patterns?
This 7,500-share sale aligns with Susi's recent cadence of smaller, routine block sales; over the past year, his average sale size has ranged from 5,000 to 10,000 shares, with this transaction reflecting the reduced share capacity as his holdings have declined. - What proportion of Roger Susi’s indirect holdings were affected?
This transaction left the Phillip Susi 2008 Dynasty Trust with approximately 2.16 million shares post-sale. - Was this a direct or indirect disposition, and are there any remaining derivative awards?
All shares sold were via indirect holdings (trust); no direct ownership or outstanding options remain following the transaction as of the filing date. - What market context is relevant for this transaction?
The sales were executed under a Rule 10b5-1 plan during a period when IRADIMED CORPORATION had posted a 77.2% one-year total return (as of May 27, 2026), with the sale price near recent highs and reflecting ongoing systematic liquidation rather than discretionary trading.
Company overview
| Metric | Value |
|---|---|
| Price (as of market close June 1, 2026) | $91.84 |
| Market capitalization | $1.17 billion |
| Revenue (TTM) | $86.3 million |
| Net income (TTM) | $23.6 million |
| 1 year total return | 60.89% |
* 1-year price performance is calculated using June 1, 2026 as the reference date.
Company snapshot
- IRADIMED develops and markets MRI-compatible medical devices, including intravenous (IV) infusion pump systems and patient vital signs monitoring systems, along with related accessories and consumables.
- The company generates revenue through direct sales representatives and independent distributors targeting the healthcare sector, with recurring income from consumables and service offerings.
- It serves hospitals, acute care facilities, and outpatient imaging centers as primary customers in both domestic and international markets.
IRADIMED Corporation is a specialized medical device manufacturer focused on MRI-compatible equipment, with a strong presence in the healthcare sector.
What this transaction means for investors
IRADIMED solves a problem most people don't think about: standard IV pumps and patient monitors can't go inside an MRI suite without risking patient safety or image quality. IRADIMED builds the equipment that can, which puts it in a market with few direct competitors and customers who rarely switch once they've standardized on a solution. That’s a dynamic common across the healthcare sector. Consumables and service contracts layer recurring revenue on top of capital equipment sales, smoothing out what would otherwise be a lumpy business. The stock's run over the past year reflects a business that has been delivering, and the CEO's plan-driven trust sales have been a weekly fixture since at least March — neither fact changes the underlying investment question. What actually matters here is whether the new infusion pump gains traction. Adoption data won't be meaningful until mid-2027, which means investors buying at today's price are essentially making a bet on a product cycle that hasn't proven itself yet. If the rollout goes well, the recurring revenue flywheel gets a significant new input. If it stalls, the current valuation looks harder to justify. That's the real variable to track.
If you’d like
